187 novel genetic variants linked to prostate cancer, revising what is known about genetic risk

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Clinical Roundup

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Immunotherapy may have potential as prostate cancer treatment, study shows

A study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a synergistic treatment approach.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Researchers identify HMGA1 as key driver in colon cancer development

A gene called high mobility group A1 may be the key that opens the door to the development of colon cancer, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, Johns Hopkins Department of Medicine, Johns Hopkins Department of Pathology and the Johns Hopkins Institute for Cell Engineering.

February 28, 2025

Vol.51 No.08

187 novel genetic variants linked to prostate cancer, revising what is known about genetic risk

YOU MAY BE INTERESTED IN

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

Immunotherapy may have potential as prostate cancer treatment, study shows

Researchers identify HMGA1 as key driver in colon cancer development

Renew today!

Subscriber content

Never miss an issue!

Login